Kuros Biosciences Ltd

KURN

Equity

ISIN CH0325814116 / Valor 32581411

SIX Swiss Exchange (2024-09-16)

CHF 19.64-1.31%

Kuros Biosciences Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Kuros Biosciences Ltd is a Swiss-headquartered global innovation company with extensive research experience in the field of biologics for spinal fusion. With a commercial and research presence across three continents and in 19 markets, the company is a key player in the development of advanced biologic solutions for spinal fusion procedures. With a strong focus on innovation and research, Kuros Biosciences Ltd is dedicated to improving patient outcomes and advancing the field of biologics in spinal surgery.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Kuros Biosciences Ltd reported a significant increase in revenue for Q1 2024. Direct MagnetOs sales rose by 155% to CHF 13.9 million, compared to CHF 5.4 million in Q1 2023. This growth highlights the company's successful expansion in the market and increased demand for its products.

Segment Sales

The total sales for Kuros Biosciences Ltd's Medical Devices segment accelerated to CHF 13.9 million in Q1 2024, up from CHF 5.6 million in Q1 2023. This substantial increase underscores the strong performance and market acceptance of the company's medical devices.

EBITDA Improvement

Kuros Biosciences Ltd's Medical Devices segment achieved a positive EBITDA of CHF 3.9 million in Q1 2024, a significant improvement from CHF 0.5 million in Q1 2023. This positive EBITDA indicates better operational efficiency and profitability within the segment.

Net Loss Reduction

The net loss for Kuros Biosciences Ltd in Q1 2024 was CHF 0.2 million, a notable reduction from the CHF 5.1 million net loss reported in Q1 2023. This reduction in net loss reflects the company's improved financial health and operational performance.

Cash Position

As of June 30, 2024, Kuros Biosciences Ltd reported cash and cash equivalents amounting to CHF 14.3 million, slightly up from CHF 14.2 million as of December 31, 2023. This stable cash position ensures the company has sufficient liquidity to support its ongoing operations and growth initiatives.

Summarized from source with an LLMView Source

Key figures

801%1Y

679%3Y

1,392%5Y

Performance

78.9%1Y

65.6%3Y

68.0%5Y

Volatility